Morgan Stanley Initiates Coverage On MapLight Therapeutics with Overweight Rating, Announces Price Target of $34
Benzinga Newsdesk 11 months ago
NewsPrice TargetInitiationAnalyst Ratings
Morgan Stanley analyst Sean Laaman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Overweight rating and announces Price Target of $34.
Morgan Stanley analyst Sean Laaman initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Overweight rating and announces Price Target of $34.